ArticlePloS one2025

Retraction: Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar.

PLOS One EditorsPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.